摘要
目的观察不同剂量非布司他治疗高尿酸血症伴痛风的效果及对机体炎性因子、血管内皮损伤因子的影响。方法选取我院2017年4月—2018年10月收治的高尿酸血症伴痛风123例,根据治疗方法的不同分为低剂量组43例、高剂量组41例和对照组39例。低剂量组和高剂量组分别予非布司他40和80mg、每日1次口服,对照组予别嘌呤醇治疗,3组疗程均为24周。治疗后比较3组疗效;3组治疗前后血清炎性因子[白细胞介素6(IL-6)、肿瘤坏死因子α(TNF-α)、过氧化物酶(MPO)]和血清血管内皮损伤因子[内皮素1(ET-1)、可溶性细胞间粘附分子1(sICAM-1)、一氧化氮(NO)]水平;3组治疗期间不良反应发生情况。结果低剂量组和高剂量组治疗后总有效率均高于对照组(P<0.05);但低剂量组和高剂量组治疗后总有效率比较差异却无统计学意义(P>0.05)。治疗后3组IL-6、TNF-α、MPO水平均降低,且低剂量组和高剂量组IL-6、TNF-α、MPO降低程度大于对照组,差异均有统计学意义(P<0.05);但低剂量组和高剂量组治疗后IL-6、TNF-α、MPO水平比较差异无统计学意义(P>0.05)。治疗后,3组ET-1、sICAM-1水平均降低,NO水平均升高,且低剂量组和高剂量组ET-1、sICAM-1降低程度及NO升高程度均大于对照组,差异有统计学意义(P<0.05);但低剂量组和高剂量组治疗后ET-1、sICAM-1、NO水平比较差异均无统计学意义(P>0.05)。低剂量组和高剂量组治疗期间总不良反应发生率均低于对照组,且低剂量组治疗期间总不良反应发生率亦低于高剂量组,差异均有统计学意义(P<0.05)。结论40mg/d非布司他能有效提高高尿酸血症伴痛风患者疗效,抑制炎性因子表达,改善血管内皮细胞功能,且用药安全性好。
ObjectiveTo observe the effect of different doses of febuxostat on gout with hyperuricemia and its effects on inflammatory factors and vascular endothelial damage factors.MethodsThe 123 cases of hyperuricemia and gout treated in our hospital from April 2017 to October 2018 were divided into 43 cases of low dose group, 41 cases of high dose group and 39 cases of control group.The low dose group and the high dose group were 40 and 80 mg to non-butadiene, 1 oral treatment per day, the control group was treated with allopurinol, and the 3 groups were all 24 weeks.Comparison of 3 groups after treatment;Serum inflammatory factors before and after treatment of 3 groups[Interleukin 6 (IL-6), tumor necrosis factor α(TNF-α), peroxidase (MPO)] And serum vascular endothelium injury factor [Endothelin 1 (ET-1), soluble intercellular adhesion molecule 1 (sICAM-1), nitric oxide (NO)] Level;Occurrence of adverse reactions during treatment in 3 groups.ResultsThe total effective rate was higher in low dose group and high dose group than in control group ( P <0.05).However, there was no significant difference in total efficiency between low dose group and high dose group( P >0.05).After the treatment, the average water of the three groups IL-6, TNF-α, and MPO decreased, and the reduction of IL-6, TNF-α, and MPO in the low dose group and the high dose group was greater than that of the control group ( P <0.05);However, there was no significant difference in the levels of IL-6, TNF-α and MPO after treatment in low dose group and high dose group ( P >0.05).After treatment, the average water of ET-1 and sICAM-1 in the three groups decreased, the average water of NO increased, and the decrease of ET-1, sICAM-1 and NO in the low-dose and high-dose groups were greater than those in the control group ( P <0.05);However, there was no significant difference in ET-1, sICAM-1 and NO levels between low dose group and high dose group ( P >0.05).The incidence of total ADR was lower than that of the control group in both the low dose group an
作者
魏晓岩
李迎婕
赵学慧
王淮淮
王会芳
贾军利
吴清雷
穆宝龙
王慧
WEI Xiao-yan;LI Ying-jie;ZHAO Xue-hui;WANG Huai-huai;WANG Hui-fang;JIA Jun-li;WU Qing-lei;MU Bao-long;WANG Hui(Department of Nephrology,the Second Affiliated Hospital of Hebei North University,Zhangjiakou,Hebei 075100,China)
出处
《临床误诊误治》
2019年第10期27-32,共6页
Clinical Misdiagnosis & Mistherapy
基金
张家口市重点研发计划项目(1921015D)
